<DOC>
	<DOCNO>NCT01683266</DOCNO>
	<brief_summary>Primary Objective : - To compare efficacy new formulation insulin glargine Lantus ( overall , regardless injection time ) term change HbA1c baseline endpoint ( schedule Month 6 ) participant type 1 diabetes mellitus Secondary Objective : - To compare HOE901-U300 Lantus give morning evening term : - Change HbA1c baseline endpoint ( schedule Month 6 ) - Change baseline endpoint ( Month 6 ) fast plasma glucose ( FPG ) , plasma glucose prior injection study drug , plasma glucose 03:00 hour , mean plasma glucose ( 8-point profile ) , glucose variability , treatment satisfaction health relate quality life participant Type 1 Diabetes Mellitus ( T1DM ) - Reaching target HbA1c value control plasma glucose ( reach target without hypoglycemia ) - Frequency occurrence diurnal distribution hypoglycemia category hypoglycemia ( symptomatic , asymptomatic , nocturnal , severe , probable relative ) - Safety tolerability HOE901-U300 include development anti-insulin antibody ( AIAs ) 12-month study period</brief_summary>
	<brief_title>Comparison New Formulation Insulin Glargine With Lantus Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>The maximum study duration approximately 54 week per participant : - Up 2-week screening period - 6-month open-label comparative efficacy safety treatment period - 6-month open-label comparative safety extension period - 48-hour post-treatment safety follow-up period</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Adult participant type 1 diabetes mellitus Exclusion criterion : HbA1c le ( &lt; ) 7.0 % ( 53 mmol/mol ) great ( &gt; ) 10 % ( 86 mmol/mol ) screen Less 1 year basal plus mealtime insulin selfmonitoring blood glucose screen visit Participants stable insulin dose ( +/20 percent total basal insulin dose ) last 30 day prior screen visit Participants use premix insulin , human regular insulin mealtime insulin and/or glucoselowering drug basal insulin mealtime analogue insulin last 3 month screen visit Use insulin pump last 6 month screen visit plan switch insulin pump next 12 month Not willing inject insulin glargine assign randomization process daily morning evening ; Severe hypoglycemia result coma/seizures , and/or hospitalization diabetic ketoacidosis last 6 month screen visit Unstable proliferative diabetic retinopathy rapidly progressive diabetic retinopathy macular edema likely require treatment ( example laser , surgical treatment injectable drug ) study period The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>